Owkin Partners with Boehringer Ingelheim for AI-Driven Cancer and Immunology Research

AI biotech firm Owkin has signed a collaborative agreement with pharmaceutical giant Boehringer Ingelheim to leverage machine learning for accelerating drug discovery in oncology and immunology.

2 Sept, 12:17 — 2 Sept, 12:17

Post Share

Sources

Showing 1 of 1 sources

star-malaysiaMixed2d ago

Owkin signs AI drug discovery deal with Boehringer for cancer, immunology - The Star

Owkin signs AI drug discovery deal with Boehringer for cancer, immunology The Star

Read full article →

Owkin Partners with Boehringer Ingelheim for AI-Driven Cancer and Immunology Research

Sources

Owkin signs AI drug discovery deal with Boehringer for cancer, immunology - The Star

Related Stories

US Military Blocks Ad Trackers on Troop Devices Over Security Concerns

Netflix Raises UK Subscription Prices for Second Time This Year, Pressuring Stock

US and China Prepare for Mid-September AI Safety Talks

White House Launches Controversial Immigration-Themed Video Games